New Amsterdam Pharma
Douglas Kling has over 20 years of experience in the pharmaceutical industry. Douglas began their career in 1998 as Manager of Clinical Research - Immunology & Oncology at Knoll Pharmaceutical Company. In 2000, they moved to Reliant Pharmaceuticals as Director of Project Management. In 2008, they joined The Medicines Company as Senior Director of Program Management. In 2009, they joined Shionogi USA, Inc. as Senior Director of Project Management. From 2010 to 2015, they worked at Omthera Pharmaceuticals, Inc. as Senior Vice President of Clinical Development & Project Management and Senior Director of Project Management. From 2015 to 2017, they worked at Matinas BioPharma as Senior Vice President of Clinical Operations. Douglas currently works at NewAmsterdam as Chief Operating Officer.
Douglas Kling obtained their BS in Biology from Duke University in 1996. Douglas then went on to pursue an MBA from Rutgers University - Newark. In 2011, they obtained a Project Management Professional (PMP) certification from the Project Management Institute.
This person is not in any offices
New Amsterdam Pharma
1 followers
Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.